Welcome, Guest
Username: Password: Remember me
The Company
  • Page:
  • 1

TOPIC: Thorn Medical acquires majority stake in Okyanos

Thorn Medical acquires majority stake in Okyanos 15 Apr 2016 06:05 #6822

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3269
  • Thank you received: 1109
This might be the start of some interesting developments :whistle:

LONDON, April 14, 2016 /PRNewswire/ --
Thorn Medical PLC ("Thorn" or the "Company"), the international healthcare group, today announces the acquisition of Okyanos Holding Company Ltd., the leading stem cell therapy centre based in the Bahamas.
Okyanos is fully licensed to provide Stem Cell based treatments for cardiovascular, lung and autoimmune diseases, as well as for orthopedic and urological conditions, neurological disorders and chronic wounds and tissue ischemia.
Jack Kaye, Thorn Medical's Chief Executive, said: "With this acquisition of a controlling stake in Okyanos, we can leverage our own stem cell research and therapy license to start providing immediate treatments for patients, rather than waiting until completion of our own facilities. Okyanos is a Cell Therapy Center of Excellence with a world-class medical and scientific team and have already successfully treated nearly 200 patients, achieving remarkable outcomes and greatly improving their quality of life."
Matthew Feshbach, Chief Executive Officer and Co-Founder of Okyanos, said, "We have developed a world-class facility, medical team and protocols using adipose(fat)- derived stem and regenerative cells (ADRCs) to treat chronic degenerative diseases. We have demonstrated clinically that multiple conditions can respond to Okyanos cell therapy in a single treatment, greatly improving the quality of life for our patients. Our advanced technologies allow us to perform real-time stem cell therapy by harvesting, isolating and returning ADRCs to the same patient in the same day."
Manuel Vianna, Chief Operating Officer and Co-Founder of Okyanos added, "We have very high patient satisfaction and are now ready to rapidly increase patient numbers. We were looking for a partner to help speed up our growth, so are delighted to have joined Thorn Medical's international healthcare group."
As Mr. Kaye summed it up, "Thorn Medical has ambitious plans for growing the company rapidly to become a major international force in the medical and healthcare arena. We plan to leverage the state-of-the-art facilities and expert staff of Okyanos to quickly become the leading human stem cell treatment company in the Western world, so I look forward to welcoming the Okyanos team to the group."

Thorn Medical PLC
Thorn Medical is a trusted expert investor and acceleration partner dedicated to breaking down the barriers to providing more efficient and effective healthcare worldwide.
With a clear focus on improving human wellbeing, it acts as an aggregator of innovative, scientifically-validated medical technology, pharmaceutical products and healthcare services businesses.
It aims to transform organisational performance through delivering best practice flexible management services that streamline operations, reduce costs, encourage cross-fertilisation, expand market reach and enhance return on capital.
Thorn Medical is dedicated to this market, with a global perspective and an understanding at first hand of the evolving challenges that healthcare businesses face in growing successfully.
Thorn Medical understands how to create value for investors, service providers and patients through building a balanced portfolio of pre-and post-revenue companies that specialise in commercialising innovative and medical technologies and services.
Thorn Medical will continue to grow both organically and through acquisitions, continually developing the enterprise and fully addressing the human health cycle and its genetic, environmental, physical and nutritional influencing factors.
Thorn Medical focuses on four areas
Disease prevention
Immunity optimisation
Disease treatment
Research & development
For further information, please visit Thorn Medical's website www.thornmedical.com

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Thorn Medical acquires majority stake in Okyanos 15 Apr 2016 06:56 #6823

  • angryharry
  • angryharry's Avatar
  • Offline
  • Junior Boarder
  • Junior Boarder
  • Posts: 35
  • Thank you received: 3
So organizations using Cytori therapy can achieve worthwhile relationships but Cytori itself can't ...

Ironic.

Please Log in or Create an account to join the conversation.

Thorn Medical acquires majority stake in Okyanos 15 Apr 2016 07:57 #6824

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3269
  • Thank you received: 1109

angryharry wrote: So organizations using Cytori therapy can achieve worthwhile relationships but Cytori itself can't ...

Ironic.


That remains to be seen - in my view. It is clear that Wallstreet had turned against SC therapy in general and Cytori in particular and my own gut feeling tells me there are more "adverse" powers at work than just the shorts :whistle:

Anyway- a lot of water has flown through the Rhine river nearby- since Cytori was the only Company in the field. We have plenty of new Companies now in the private sector and hundreds of clinics using SVF as miracle cure for everything. Still Cytori is still apparently the only Company with a meaningful relationship with the FDA and that same FDA will once and for all settle its overview rules and regulations in 2016 (I hope), still all is not lost.
In Europe and Japan there are different but at least positive developments in place seemingly to the benefit of pharma like SC technology. However I still think that will not work or lets say "work poorly and unconvincingly" and that auto will prevail in the practice of medicine type environment adapted by global health authorities.

To me its still just a matter of time- with the crew at Callan Road not seeing the writing on the wall and drowning in their own self-esteem, I will definitely keep a close eye on developments like with Thorn Medical - a Company I was tipped on a few months ago to have a look at- also in view of some interest they were apparently taking in the Bahama´s.

Anyway- the investment climate in the UK has turned positive to the technology ( or was never that beaten down- lets say) and Thorn Medical might use that to IPO in the UK- the Oxford-London-Cambridge triangle should be kept an eye on, which I will. :grin:

That last sentence I "borrowed" from an excellent article I found on their website-

How SMEs Can Rise to the Challenges of Healthcare

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Thorn Medical acquires majority stake in Okyanos 15 Apr 2016 10:18 #6827

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 870
  • Thank you received: 148
This is an interesting development and the first question to be asked is ... WHY? Is this strategic in some way or evidence that Okyanos never went cash flow positive and needed capital to stay afloat. Was this done at a richer or cheaper valuation than the last round of financing. I have no idea what the answers are to these questions but they are critical in understanding what has taken place here, Okyanos had to compete with hundreds of SVF stem cell clinics operating in the U.S.illegally with more competitive pricing, even if the technology may not have provided the same quality of SVF output. Unfortunately for Okyanos, the average patient wouldn't know the difference. Anybody have any answers?

Please Log in or Create an account to join the conversation.

Thorn Medical acquires majority stake in Okyanos 15 Apr 2016 11:53 #6828

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2742
  • Thank you received: 199
Good questions WST and ones that also crossed my mind....this may not be as positive as it seems...at least for Okyanos investors.

I know at least one lodge member stated that Okyanos would not live up to the hyped cardiac numbers and they were darn lucky to be able to expand on the applications. I wonder if this person has a view on the number of burn patients that will be treated in 2020? :winky:

Please Log in or Create an account to join the conversation.

Thorn Medical acquires majority stake in Okyanos 15 Apr 2016 13:06 #6829

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 870
  • Thank you received: 148
Thorn Medical has already CURED baldness . 100% effective! Why didn't I know about this?? Supposedly this company is planning a $350MM IPO Strange..

Please Log in or Create an account to join the conversation.

Thorn Medical acquires majority stake in Okyanos 15 Apr 2016 16:44 #6830

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 870
  • Thank you received: 148
Okyanos had no shot to live up to the cardiac numbers because Cytori let them down. Recall they applied to expand the Celution System CE Mark to include no-option CMI claims in Europe based on this on PRECISE and never got anywhere with it. A long list in the list of promises unkept. I recall that that pending EU CMI approval was the basis for setting up Okyanos in the first place and the focus of much optimism here.

Flashback: Monday, December 19, 2011

San Diego-based Cytori Therapeutics (Nasdaq: CYTX) filed its Investigational Device Exemption (IDE) application to begin a clinical trial of the company's Celution System for chronic myocardial ischemia (CMI).

Athena is a device-based safety and feasibility trial (Phase 1/2) to investigate the use of autologous, clinical-grade adipose tissue-derived stem and regenerative cells (ADRCs), processed at the point-of-care with Cytori's proprietary Celution System. The submission initiates a review process with the Food and Drug Administration before approval is granted to begin the trial.

Previously, Cytori reported six- and 18-month trial data from Precise, a European clinical trial for this same indication showing statistically significant improvement in cardiac functional capacity, which was incorporated into the U.S. IDE filing.
In addition, Cytori has applied to expand its Celution System CE Mark to include no-option CMI claims in Europe based on this data. Cytori is also enrolling a European pivotal trial using the Celution System for acute heart attacks.
No-option CMI is estimated to affect approximately 6 percent of all coronary heart disease patients worldwide. In the United States, more than 1 million patients are in this class with an annual cost of more than $10 billion. CMI patients typically have undergone multiple revascularization procedures, may suffer from serious abnormal heart rhythms, and have few therapeutic options. One goal of cell therapy in CMI is to revive hibernating heart muscle, which is living tissue that is not contributing to the pumping action of the heart.

Please Log in or Create an account to join the conversation.

Thorn Medical acquires majority stake in Okyanos 16 Apr 2016 07:36 #6831

  • cytxer
  • cytxer's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 347
  • Thank you received: 25
It seems that Thorn was looking for a facility and might not be looking for technology?

Anyway, I didn't see a mention of Celution... though I am reading without my glasses. :grin:

Please Log in or Create an account to join the conversation.

Thorn Medical acquires majority stake in Okyanos 16 Apr 2016 09:43 #6832

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3269
  • Thank you received: 1109

Wall Street Titan wrote: Okyanos had no shot to live up to the cardiac numbers because Cytori let them down. Recall they applied to expand the Celution System CE Mark to include no-option CMI claims in Europe based on this on PRECISE and never got anywhere with it. A long list in the list of promises unkept. I recall that that pending EU CMI approval was the basis for setting up Okyanos in the first place and the focus of much optimism here.

Flashback: Monday, December 19, 2011

San Diego-based Cytori Therapeutics (Nasdaq: CYTX) filed its Investigational Device Exemption (IDE) application to begin a clinical trial of the company's Celution System for chronic myocardial ischemia (CMI).

Athena is a device-based safety and feasibility trial (Phase 1/2) to investigate the use of autologous, clinical-grade adipose tissue-derived stem and regenerative cells (ADRCs), processed at the point-of-care with Cytori's proprietary Celution System. The submission initiates a review process with the Food and Drug Administration before approval is granted to begin the trial.

Previously, Cytori reported six- and 18-month trial data from Precise, a European clinical trial for this same indication showing statistically significant improvement in cardiac functional capacity, which was incorporated into the U.S. IDE filing.
In addition, Cytori has applied to expand its Celution System CE Mark to include no-option CMI claims in Europe based on this data. Cytori is also enrolling a European pivotal trial using the Celution System for acute heart attacks.
No-option CMI is estimated to affect approximately 6 percent of all coronary heart disease patients worldwide. In the United States, more than 1 million patients are in this class with an annual cost of more than $10 billion. CMI patients typically have undergone multiple revascularization procedures, may suffer from serious abnormal heart rhythms, and have few therapeutic options. One goal of cell therapy in CMI is to revive hibernating heart muscle, which is living tissue that is not contributing to the pumping action of the heart.


Everything perfectly correct... :yep:

Instead of approval for no-option CMI the following approval was received and announcement made "after a long long wait"

Intravase® Approval Opens Vascular Market for Cytori
02/25/2013

Cytori Receives CE Mark for Specialized Cell Therapy Reagent for Intravascular Delivery

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) has received a CE Mark in Europe for Intravase®, a reagent intended to be used with Cytori’s Celution® System for preparing safe and optimized adipose-derived stem and regenerative cells (ADRCs) for intravascular delivery into the same patient.

“This approval expands our market access for our cell therapy platform to include intravascular applications,” said Marc Hedrick , President of Cytori Therapeutics. “As a result, this is expected to contribute to revenue growth in 2013 and beyond. We will target select centers to build patient data, which we believe can be used to further expand these claims and increase the adoption of our technology. Furthermore, CE Mark approval of Intravase will allow independent European investigators to conduct their own vascular studies.”

Intravase is a sterile, GMP-grade secondary reagent used with the Celution System to prepare the Celution cell output for safe intravascular delivery. Intravase is currently being used in both our U.S. ATHENA trial in patients with refractory heart failure due to chronic myocardial ischemia and the European ADVANCE trial for acute heart attack patients.


I recall vividly that HEDRICK claimed in the call following the announcement, that they received 90% of what they were looking for...

Thats the last we have heard from ADRCs conquering the cardiac SC market in Europe besides sneaking some slides into presentations, which only I picked up, and which claimed that several organ- or cardiac related private investigator trials were ongoing- presumably in Europe.

And that guy got the baton from Calhoun... :puke:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Thorn Medical acquires majority stake in Okyanos 16 Apr 2016 11:10 #6833

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3269
  • Thank you received: 1109

fas wrote:
I recall vividly that HEDRICK claimed in the call following the announcement, that they received 90% of what they were looking for...

Thats the last we have heard from ADRCs conquering the cardiac SC market in Europe besides sneaking some slides into presentations, which only I picked up, and which claimed that several organ- or cardiac related private investigator trials were ongoing- presumably in Europe.

And that guy got the baton from Calhoun... :puke:


1. so now we have a relatively new established UK Company looking for SME´s to make an impact on "the new way in medicine"
2. which Company according to some is also on the look-out for real-estate :joy:
3. we have Calhoun/Perin/Lampert desperately trying to tackle a task which Calhoun failed to accomplish as CEO of Cytori
4. we have Hedrick/Cytori refusing to inform shareholders of ADVANCE results and making up sob stories why ATHENA data has not been reported upon
5. Eric Duckers still in the thick of things at UMC and at the same time now liaised with Thorn Medical
6. And three years plus a few months after the fact more data for insiders are surely available for cardiac applications- see above PI clinics etc.......

I think something has to break... :bye:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Thorn Medical acquires majority stake in Okyanos 17 Apr 2016 12:43 #6834

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3269
  • Thank you received: 1109
To "sign off" on Thorn Medical for the time being- I really do not think they will be involved with Cytori in the foreseeable future- but what isnt may come sometime or grow, once they know the actual clinical experience from Okyanos and might even decide to build clinics elsewhere in the world after seeing what ADRCs can do .. :whistle:

Anyway- the need to do their IPO first, which hasnt happened yet..

this is from February-



and an article in the telegraph is interesting reading too:



link to article: Sunday Telegraph Article on Thorn Medical
Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Thorn Medical acquires majority stake in Okyanos 17 Apr 2016 16:20 #6835

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 870
  • Thank you received: 148
So Thorn was just founded in 2014, has a 100% cure for baldness, is already worth $340,000,000 and will worth more than double that in a year and is at the forefront of stem cell medicine (while also being involved in clinical waste)?? I think I'd like to see a set of financials before I judge.

This quote from the article says it all....

“We can repair tendons, torn ligaments, do spinal chord reconstructions, overhaul immune systems and grow everything from new arms to hearts. In theory, you could live for ever,” he said.

WST

Please Log in or Create an account to join the conversation.

Thorn Medical acquires majority stake in Okyanos 18 Apr 2016 02:59 #6836

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3269
  • Thank you received: 1109

Wall Street Titan wrote: So Thorn was just founded in 2014, has a 100% cure for baldness, is already worth $340,000,000 and will worth more than double that in a year and is at the forefront of stem cell medicine (while also being involved in clinical waste)?? I think I'd like to see a set of financials before I judge.

This quote from the article says it all....

“We can repair tendons, torn ligaments, do spinal chord reconstructions, overhaul immune systems and grow everything from new arms to hearts. In theory, you could live for ever,” he said.

WST


Some of the statements do remind of statements made by early entrepreneurs in the SC field 10 years ago.. :whistle:

On the other hand, they picked up several pre-revenue businesses and spent 75 Mio Pounds on the assets according to the financials that you can find on their page.
But that is as of June 30 2015- surely they have not been poking in their nose since than and Kaye and Lord Beaverbrook are/have been extremely successful business men with traceable track records.. :yep:

File Attachment:

File Name: thorn-interim-unaudited-accounts-june-2015.pdf
File Size: 418 KB
Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.742 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites